BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30016448)

  • 1. Anaplastic Large Cell Lymphoma Manifesting as Pleural Effusion in a Patient with Long-Standing Eosinophilia.
    Belludi CK; Qian ET; Tolle JJ; Brown RM; Thompson MA; Juskevicius R
    Lab Med; 2019 Jan; 50(1):87-92. PubMed ID: 30016448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathology and genetics of anaplastic large cell lymphoma.
    Leventaki V; Bhattacharyya S; Lim MS
    Semin Diagn Pathol; 2020 Jan; 37(1):57-71. PubMed ID: 31882178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALCL by any other name: the many facets of anaplastic large cell lymphoma.
    Irshaid L; Xu ML
    Pathology; 2020 Jan; 52(1):100-110. PubMed ID: 31706671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytological features of breast implant-associated anaplastic large cell lymphoma in pleural effusion.
    D'Alessandris N; Lucatelli P; Tripodi D; Amabile MI; Ascoli V
    Diagn Cytopathol; 2019 Nov; 47(11):1213-1217. PubMed ID: 31348611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to Diagnose Anaplastic Large Cell Lymphoma on Cytological Samples? A Series with Emphasis on Diagnostic Clue and Pitfalls.
    Montella M; LucĂ  S; Ronchi A; Marino FZ; Caputo A; Sica A; Zeppa P; Franco R; Cozzolino I
    Acta Cytol; 2023; 67(3):230-239. PubMed ID: 36634640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination.
    ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Pulford K; Willemze R; Falini B; Chott A; Meijer CJ
    J Clin Pathol; 2000 Jun; 53(6):445-50. PubMed ID: 10911802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous.
    Xing X; Feldman AL
    Adv Anat Pathol; 2015 Jan; 22(1):29-49. PubMed ID: 25461779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic ALK-negative anaplastic large cell lymphoma with distinctive myxoid change and DUSP22 rearrangement.
    Fratoni S; Trawinska MM; Capalbo A; Bernardini L; Fabbretti M; Martini M; Niscola P; Zhao XF
    Virchows Arch; 2022 Dec; 481(6):975-979. PubMed ID: 35879438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
    Shustov A; Soma L
    Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.
    Querfeld C; Khan I; Mahon B; Nelson BP; Rosen ST; Evens AM
    Oncology (Williston Park); 2010 Jun; 24(7):574-87. PubMed ID: 20669794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary effusion anaplastic large cell lymphoma with indolent clinical course and IRF4/DUSP22 rearrangement: a case report expanding the spectrum of effusion-based lymphoma.
    Yuan CT; Cheng AL; Hou HA
    Virchows Arch; 2023 Mar; 482(3):641-645. PubMed ID: 35984488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinicopathological relevance of uniform CD56 expression in anaplastic large cell lymphoma: a retrospective analysis of 18 cases.
    Yu BH; Zhang Y; Xue T; Shui RH; Lu HF; Zhou XY; Zhu XZ; Li XQ
    Diagn Pathol; 2021 Jan; 16(1):1. PubMed ID: 33402163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaplastic large cell lymphoma in leukemic phase: extraordinarily high white blood cell count.
    Nguyen JT; Condron MR; Nguyen ND; De J; Medeiros LJ; Padula A
    Pathol Int; 2009 May; 59(5):345-53. PubMed ID: 19432678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment.
    Zhang XR; Chien PN; Nam SY; Heo CY
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal ALK-negative systemic anaplastic large cell lymphoma presenting with disseminated cutaneous dome-shaped papules and nodules.
    Bird JE; Leitenberger JJ; Solomon A; Blauvelt A; Hopkins S
    Dermatol Online J; 2012 May; 18(5):5. PubMed ID: 22630575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary ALK-1-negative anaplastic large cell lymphoma of the brain: case report and review of the literature.
    Kodama K; Hokama M; Kawaguchi K; Tanaka Y; Hongo K
    Neuropathology; 2009 Apr; 29(2):166-71. PubMed ID: 18564100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma.
    Ravindran A; Feldman AL; Ketterling RP; Dasari S; Rech KL; McPhail ED; Kurtin PJ; Shi M
    Am J Surg Pathol; 2021 Apr; 45(4):550-557. PubMed ID: 33165091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior.
    Gerbe A; Alame M; Dereure O; Gonzalez S; Durand L; Tempier A; De Oliveira L; Tourneret A; Costes-Martineau V; Cacheux V; Szablewski V
    Virchows Arch; 2019 Aug; 475(2):163-174. PubMed ID: 30953147
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.